The present study demonstrated that nucleolin co-expression at the cell surface of endothelial cells in vitro and tumor-associated blood vessels in vivo is required for the antiangiogenic and antitumoral actions of kallistatin. This evidence concerns the gene SERPINA4 and neoplasm.